Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Lebret

Showing results (131-140 of 147) with videos related to

Pageof 15
Sort By:
The Lancet. Oncology|May 17, 2015
A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studiesBrian Rini, Audrey Goddard, Dejan Knezevic, et al.
BMJ Open|December 21, 2023
Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of lifeThierry Lebret, Julia Bonastre, Aldéric Fraslin, et al.
European Urology|June 30, 2021
Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2024
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274Matthew D Galsky, Johannes Alfred Witjes, Jürgen E Gschwend, et al.
Plos One|December 29, 2012
A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancerYann Neuzillet, Xavier Paoletti, Slah Ouerhani, et al.
Acta Oncologica (Stockholm, Sweden)|February 21, 2013
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysisBenoit Beuselinck, Alexandra Karadimou, Diether Lambrechts, et al.
European Urology|October 23, 2022
FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex BiasMing-Jun Shi, Jacqueline Fontugne, Aura Moreno-Vega, et al.
Science Translational Medicine|July 11, 2014
EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotypeSandra Rebouissou, Isabelle Bernard-Pierrot, Aurélien de Reyniès, et al.
The Lancet. Oncology|May 13, 2024
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trialAndrea Necchi, Mathieu Roumiguié, Ashish M Kamat, et al.
The New England Journal of Medicine|June 5, 2018
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell CarcinomaArnaud Méjean, Alain Ravaud, Simon Thezenas, et al.
Pageof 15

Showing results (131-140 of 147) with videos related to

Sort By:
Pageof 15
The Lancet. Oncology|May 17, 2015
A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studiesBrian Rini, Audrey Goddard, Dejan Knezevic, et al.
BMJ Open|December 21, 2023
Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of lifeThierry Lebret, Julia Bonastre, Aldéric Fraslin, et al.
European Urology|June 30, 2021
Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2024
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274Matthew D Galsky, Johannes Alfred Witjes, Jürgen E Gschwend, et al.
Plos One|December 29, 2012
A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancerYann Neuzillet, Xavier Paoletti, Slah Ouerhani, et al.
Acta Oncologica (Stockholm, Sweden)|February 21, 2013
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysisBenoit Beuselinck, Alexandra Karadimou, Diether Lambrechts, et al.
European Urology|October 23, 2022
FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex BiasMing-Jun Shi, Jacqueline Fontugne, Aura Moreno-Vega, et al.
Science Translational Medicine|July 11, 2014
EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotypeSandra Rebouissou, Isabelle Bernard-Pierrot, Aurélien de Reyniès, et al.
The Lancet. Oncology|May 13, 2024
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trialAndrea Necchi, Mathieu Roumiguié, Ashish M Kamat, et al.
The New England Journal of Medicine|June 5, 2018
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell CarcinomaArnaud Méjean, Alain Ravaud, Simon Thezenas, et al.
Pageof 15